High levels of high-density lipoprotein (HDL or “good” cholesterol) and apolipoprotein A1 (apoA1) in women appears to lower the risk of cardiovascular disease.
Online PR News – 15-December-2009 – – According to new research conducted at Brigham and Women's Hospital, high levels of high-density lipoprotein (HDL or "good" cholesterol) and apolipoprotein A1 (apoA1) in women appears to lower the risk of cardiovascular disease across all levels of low-density lipoprotein (LDL, "bad" cholesterol). These findings were presented at the American Heart Association Scientific Sessions on November 19, 2009.
Researchers led by Samia Mora, M.D, MHSc, a researcher and clinician in the Cardiovascular Division at BWH, measured baseline cholesterol and apoA1 in nearly 28,000 apparently healthy women with an average age of 55 years. The women were followed for 11 years for their first cardiovascular disease events. Researchers found a strong inverse association between HDL, apoA1 (a major protein component in HDL) and the risk for cardiovascular disease. The association of HDL with cardiovascular disease was consistent no matter the levels of LDL and similarly for apoA1. Women with HDL above 69 milligrams/deciliter (mg/dL) had cardiovascular disease onset 10 years later than women with HDL below 35 mg/dL.
About Brigham and Women's Hospital:-
Brigham and Women's Hospital (BWH) is a 777-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. In July of 2008, the hospital opened the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 860 physician-investigators and renowned biomedical scientists and faculty supported by more than $416 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information about BWH, please visit http://www.brighamandwomens.org/